Esteban Pineda Arias

Esteban Pineda Arias

Auto-generated profile, based on publicly available information

Esteban Pineda Arias

Unidad Central del Valle del Cauca

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2026 in Global Cardiology Science and Practice
Verified
Journal Article
Open access
PDF file
DLDiego Fernando Lopez
Diego Fernando Lopez
CVCristhian Camilo Velandia-Mosquera
Cristhian Camilo Velandia-Mosquera
OCOscar Eduardo Cruz-Becerra
Oscar Eduardo Cruz-Becerra
DADaniela Andrea Agudelo
Daniela Andrea Agudelo
EAEsteban Pineda Arias
Esteban Pineda Arias
MGMartha Liliana Girón Girón
Martha Liliana Girón Girón
Objective: To evaluate the prognostic value of mean platelet volume (MPV) for cardiovascular risk stratification in settings with limited resources. Methods: We conducted a comprehensive systematic review in accordance with the PRISMA 2020 guidelines (PROSPERO registration number: CRD420251156089). From January 2019 to December 2024, we searched five databases (PubMed, Scopus, Web of Science, SciELO and LILACS) for observational studies linking MPV to cardiovascular outcomes. The methodological quality of the studies was assessed using the STROBE criteria, and the certainty of the evidence was assessed using the GRADE approach. Results: Thirteen studies involving 3,085 participants were included. Of these, 12 (92.3%) reported statistically significant associations between elevated mean platelet volume (MPV) and an increased risk of acute myocardial infarction, stroke, and thromboembolism. MPV values in patients experiencing acute events (8.4–10.7 fL) were consistently higher than in the control group. Derived indices, particularly the MPV-to-lymphocyte ratio, demonstrated superior predictive utility compared to MPV alone. However, critical limitations included substantial heterogeneity in the cut-off point (7.45–12 fL), pre-analytical variability and the complete absence of Latin American populations. The overall certainty of the evidence was classified as VERY LOW. Conclusion: Although there is a consistent predictive signal across worldwide cohorts, its current application in clinical practice is prohibited by the VERY LOW certainty of evidence, which is caused by high pre-analytical heterogeneity and a total lack of Latin American data. These results show that MPV should be prioritized for standardized validation studies rather than being used right away in clinical settings.